Benzinga · Jan 26, 2022
The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead Hit With FDA Partial Clinical Hold On Multiple Blood Cancer Studies Evaluating Magrolimab-Vidaza Combo Gilead Sciences, Inc. (NASDAQ: GILD) said the U.S. Food and Drug Administration has placed a partial clinical hold on studies evaluating the combination of magrolimab plus Bristol-Myers Squibb Co's (NYSE: BMY) Vidaza due to an apparent imbalance in investigator-reported suspected unexpected serious adverse reactions between study arms. While no clear trend in the adverse reactions or new safety signal has been identified by Gilead at this time, the partial clinical hold is being implemented by Gilead across all ongoing magrolimab and Vidaza combination studies worldwide in the best interests of patients as additional data is gathered and analyzed to address the concerns raised by FDA. The stock was down 1.44% at $67.85 in premarket trading. Click here to access Benzinga's FDA Calendar MediciNova Receives Notice Of Intent to Grant European Patent Related to MN-001 & MN-002 In Hepatic Ballooning MediciNova, Inc., (NASDAQ: MNOV) announced that it has received a notice of intention to grant from the European Patent Office for a pending patent application that covers MN-001 and MN-002, a major metabolite of MN-001, for hepatic ballooning. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than January 2035. The allowed claims cover the use of ...
